Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Operating Expenses: 2020-2025

Historic Other Operating Expenses for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $4.8 million.

  • Insight Molecular Diagnostics' Other Operating Expenses fell 41.78% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 68.16%. This contributed to the annual value of $41.7 million for FY2024, which is 722.75% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Other Operating Expenses of $4.8 million as of Q3 2025, which was up 11.73% from $4.3 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Other Operating Expenses' 5-year high stood at $29.4 million during Q4 2024, with a 5-year trough of -$11.4 million in Q1 2023.
  • Moreover, its 3-year median value for Other Operating Expenses was $4.3 million (2025), whereas its average is $5.3 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first tumbled by 701.90% in 2023, then soared by 2,495.51% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Other Operating Expenses (Quarterly) stood at $9.1 million in 2021, then crashed by 43.09% to $5.2 million in 2022, then spiked by 128.14% to $11.8 million in 2023, then skyrocketed by 149.99% to $29.4 million in 2024, then tumbled by 41.78% to $4.8 million in 2025.
  • Its Other Operating Expenses was $4.8 million in Q3 2025, compared to $4.3 million in Q2 2025 and $2.1 million in Q1 2025.